The global Denosumab Injection market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Denosumab injection is a medication used primarily to treat bone-related conditions such as osteoporosis, particularly in patients at high risk of fractures, as well as for bone loss associated with cancer.

From a downstream perspective, Giant Cell Tumor of Bone accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Denosumab Injection leading manufacturers including Amgen, Sandoz Biologics, Amneal, Fresenius Kabi, Dr. Reddy's Laboratories, Alvotech, Lotus Pharmaceutical, Intas Pharmaceuticals, Qilu Pharmaceutical, Jiangsu T-mab BioPharma, etc., dominate supply; the top five capture approximately % of global revenue, with Amgen leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Denosumab Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Denosumab Injection Market Report

Report Metric	Details
Report Name	Denosumab Injection Market
Segment by Type	60mg per Vial 120mg per Vial
Segment by Application	Giant Cell Tumor of Bone Multiple Myeloma Hypercalcemia of Malignant Tumors Osteolytic Bone Metastasis of Solid Tumors
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen, Sandoz Biologics, Amneal, Fresenius Kabi, Dr. Reddy's Laboratories, Alvotech, Lotus Pharmaceutical, Intas Pharmaceuticals, Qilu Pharmaceutical, Jiangsu T-mab BioPharma, Boan Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Denosumab Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Denosumab Injection Market report?

Ans: The main players in the Denosumab Injection Market are Amgen, Sandoz Biologics, Amneal, Fresenius Kabi, Dr. Reddy's Laboratories, Alvotech, Lotus Pharmaceutical, Intas Pharmaceuticals, Qilu Pharmaceutical, Jiangsu T-mab BioPharma, Boan Biotech

What are the Application segmentation covered in the Denosumab Injection Market report?

Ans: The Applications covered in the Denosumab Injection Market report are Giant Cell Tumor of Bone, Multiple Myeloma, Hypercalcemia of Malignant Tumors, Osteolytic Bone Metastasis of Solid Tumors

What are the Type segmentation covered in the Denosumab Injection Market report?

Ans: The Types covered in the Denosumab Injection Market report are 60mg per Vial, 120mg per Vial

1 Study Coverage

1.1 Introduction to Denosumab Injection: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Denosumab Injection Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 60mg per Vial

1.2.3 120mg per Vial

1.3 Market Segmentation by Application

1.3.1 Global Denosumab Injection Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Giant Cell Tumor of Bone

1.3.3 Multiple Myeloma

1.3.4 Hypercalcemia of Malignant Tumors

1.3.5 Osteolytic Bone Metastasis of Solid Tumors

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Denosumab Injection Revenue Estimates and Forecasts 2020-2031

2.2 Global Denosumab Injection Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Denosumab Injection Sales Estimates and Forecasts 2020-2031

2.4 Global Denosumab Injection Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Denosumab Injection Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Denosumab Injection Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 60mg per Vial Market Size by Manufacturers

3.5.2 120mg per Vial Market Size by Manufacturers

3.6 Global Denosumab Injection Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Denosumab Injection Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Denosumab Injection Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Denosumab Injection Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Denosumab Injection Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Denosumab Injection Sales and Revenue by Type (2020-2031)

6.4 North America Denosumab Injection Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Denosumab Injection Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Denosumab Injection Sales and Revenue by Type (2020-2031)

7.4 Europe Denosumab Injection Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Denosumab Injection Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Denosumab Injection Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Denosumab Injection Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Denosumab Injection Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Denosumab Injection Sales and Revenue by Type (2020-2031)

9.4 Central and South America Denosumab Injection Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Denosumab Injection Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Denosumab Injection Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Denosumab Injection Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Denosumab Injection Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Amgen

11.1.1 Amgen Corporation Information

11.1.2 Amgen Business Overview

11.1.3 Amgen Denosumab Injection Product Models, Descriptions and Specifications

11.1.4 Amgen Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Amgen Denosumab Injection Sales by Product in 2024

11.1.6 Amgen Denosumab Injection Sales by Application in 2024

11.1.7 Amgen Denosumab Injection Sales by Geographic Area in 2024

11.1.8 Amgen Denosumab Injection SWOT Analysis

11.1.9 Amgen Recent Developments

11.2 Sandoz Biologics

11.2.1 Sandoz Biologics Corporation Information

11.2.2 Sandoz Biologics Business Overview

11.2.3 Sandoz Biologics Denosumab Injection Product Models, Descriptions and Specifications

11.2.4 Sandoz Biologics Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Sandoz Biologics Denosumab Injection Sales by Product in 2024

11.2.6 Sandoz Biologics Denosumab Injection Sales by Application in 2024

11.2.7 Sandoz Biologics Denosumab Injection Sales by Geographic Area in 2024

11.2.8 Sandoz Biologics Denosumab Injection SWOT Analysis

11.2.9 Sandoz Biologics Recent Developments

11.3 Amneal

11.3.1 Amneal Corporation Information

11.3.2 Amneal Business Overview

11.3.3 Amneal Denosumab Injection Product Models, Descriptions and Specifications

11.3.4 Amneal Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Amneal Denosumab Injection Sales by Product in 2024

11.3.6 Amneal Denosumab Injection Sales by Application in 2024

11.3.7 Amneal Denosumab Injection Sales by Geographic Area in 2024

11.3.8 Amneal Denosumab Injection SWOT Analysis

11.3.9 Amneal Recent Developments

11.4 Fresenius Kabi

11.4.1 Fresenius Kabi Corporation Information

11.4.2 Fresenius Kabi Business Overview

11.4.3 Fresenius Kabi Denosumab Injection Product Models, Descriptions and Specifications

11.4.4 Fresenius Kabi Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Fresenius Kabi Denosumab Injection Sales by Product in 2024

11.4.6 Fresenius Kabi Denosumab Injection Sales by Application in 2024

11.4.7 Fresenius Kabi Denosumab Injection Sales by Geographic Area in 2024

11.4.8 Fresenius Kabi Denosumab Injection SWOT Analysis

11.4.9 Fresenius Kabi Recent Developments

11.5 Dr. Reddy's Laboratories

11.5.1 Dr. Reddy's Laboratories Corporation Information

11.5.2 Dr. Reddy's Laboratories Business Overview

11.5.3 Dr. Reddy's Laboratories Denosumab Injection Product Models, Descriptions and Specifications

11.5.4 Dr. Reddy's Laboratories Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Dr. Reddy's Laboratories Denosumab Injection Sales by Product in 2024

11.5.6 Dr. Reddy's Laboratories Denosumab Injection Sales by Application in 2024

11.5.7 Dr. Reddy's Laboratories Denosumab Injection Sales by Geographic Area in 2024

11.5.8 Dr. Reddy's Laboratories Denosumab Injection SWOT Analysis

11.5.9 Dr. Reddy's Laboratories Recent Developments

11.6 Alvotech

11.6.1 Alvotech Corporation Information

11.6.2 Alvotech Business Overview

11.6.3 Alvotech Denosumab Injection Product Models, Descriptions and Specifications

11.6.4 Alvotech Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Alvotech Recent Developments

11.7 Lotus Pharmaceutical

11.7.1 Lotus Pharmaceutical Corporation Information

11.7.2 Lotus Pharmaceutical Business Overview

11.7.3 Lotus Pharmaceutical Denosumab Injection Product Models, Descriptions and Specifications

11.7.4 Lotus Pharmaceutical Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Lotus Pharmaceutical Recent Developments

11.8 Intas Pharmaceuticals

11.8.1 Intas Pharmaceuticals Corporation Information

11.8.2 Intas Pharmaceuticals Business Overview

11.8.3 Intas Pharmaceuticals Denosumab Injection Product Models, Descriptions and Specifications

11.8.4 Intas Pharmaceuticals Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Intas Pharmaceuticals Recent Developments

11.9 Qilu Pharmaceutical

11.9.1 Qilu Pharmaceutical Corporation Information

11.9.2 Qilu Pharmaceutical Business Overview

11.9.3 Qilu Pharmaceutical Denosumab Injection Product Models, Descriptions and Specifications

11.9.4 Qilu Pharmaceutical Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Qilu Pharmaceutical Recent Developments

11.10 Jiangsu T-mab BioPharma

11.10.1 Jiangsu T-mab BioPharma Corporation Information

11.10.2 Jiangsu T-mab BioPharma Business Overview

11.10.3 Jiangsu T-mab BioPharma Denosumab Injection Product Models, Descriptions and Specifications

11.10.4 Jiangsu T-mab BioPharma Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Jiangsu T-mab BioPharma Recent Developments

11.11 Boan Biotech

11.11.1 Boan Biotech Corporation Information

11.11.2 Boan Biotech Business Overview

11.11.3 Boan Biotech Denosumab Injection Product Models, Descriptions and Specifications

11.11.4 Boan Biotech Denosumab Injection Sales, Price, Revenue and Gross Margin (2020-2025)

11.11.5 Boan Biotech Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Denosumab Injection Industry Chain

12.2 Denosumab Injection Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Denosumab Injection Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Denosumab Injection Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Denosumab Injection Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Denosumab Injection Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Dr. Reddy’s Laboratories

Alvotech

Lotus Pharmaceutical

Intas Pharmaceuticals

Qilu Pharmaceutical

Boan Biotech

Sandoz Biologics

Jiangsu T-mab BioPharma

List of Tables

Table 1. Global Denosumab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Denosumab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Denosumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Denosumab Injection Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Denosumab Injection Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Denosumab Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Denosumab Injection Sales by Region (2020-2025) & (K Units)

Table 8. Global Denosumab Injection Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Denosumab Injection Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Denosumab Injection Sales Share by Manufacturers (2020-2025)

Table 12. Global Denosumab Injection Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Denosumab Injection Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Denosumab Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Denosumab Injection as of 2024)

Table 16. Global Denosumab Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Denosumab Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Denosumab Injection Manufacturing Base and Headquarters

Table 19. Global Denosumab Injection Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Denosumab Injection Sales by Type (2020-2025) & (K Units)

Table 23. Global Denosumab Injection Sales by Type (2026-2031) & (K Units)

Table 24. Global Denosumab Injection Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Denosumab Injection Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Denosumab Injection ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Denosumab Injection Sales by Application (2020-2025) & (K Units)

Table 29. Global Denosumab Injection Sales by Application (2026-2031) & (K Units)

Table 30. Denosumab Injection High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Denosumab Injection Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Denosumab Injection Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Denosumab Injection ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Denosumab Injection Growth Accelerators and Market Barriers

Table 37. North America Denosumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Denosumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Denosumab Injection Growth Accelerators and Market Barriers

Table 40. Europe Denosumab Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Denosumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Denosumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Denosumab Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Denosumab Injection Growth Accelerators and Market Barriers

Table 45. Southeast Asia Denosumab Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Denosumab Injection Investment Opportunities and Key Challenges

Table 47. Central and South America Denosumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Denosumab Injection Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Denosumab Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Amgen Corporation Information

Table 51. Amgen Description and Major Businesses

Table 52. Amgen Product Models, Descriptions and Specifications

Table 53. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Amgen Sales Value Proportion by Product in 2024

Table 55. Amgen Sales Value Proportion by Application in 2024

Table 56. Amgen Sales Value Proportion by Geographic Area in 2024

Table 57. Amgen Denosumab Injection SWOT Analysis

Table 58. Amgen Recent Developments

Table 59. Sandoz Biologics Corporation Information

Table 60. Sandoz Biologics Description and Major Businesses

Table 61. Sandoz Biologics Product Models, Descriptions and Specifications

Table 62. Sandoz Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Sandoz Biologics Sales Value Proportion by Product in 2024

Table 64. Sandoz Biologics Sales Value Proportion by Application in 2024

Table 65. Sandoz Biologics Sales Value Proportion by Geographic Area in 2024

Table 66. Sandoz Biologics Denosumab Injection SWOT Analysis

Table 67. Sandoz Biologics Recent Developments

Table 68. Amneal Corporation Information

Table 69. Amneal Description and Major Businesses

Table 70. Amneal Product Models, Descriptions and Specifications

Table 71. Amneal Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Amneal Sales Value Proportion by Product in 2024

Table 73. Amneal Sales Value Proportion by Application in 2024

Table 74. Amneal Sales Value Proportion by Geographic Area in 2024

Table 75. Amneal Denosumab Injection SWOT Analysis

Table 76. Amneal Recent Developments

Table 77. Fresenius Kabi Corporation Information

Table 78. Fresenius Kabi Description and Major Businesses

Table 79. Fresenius Kabi Product Models, Descriptions and Specifications

Table 80. Fresenius Kabi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Fresenius Kabi Sales Value Proportion by Product in 2024

Table 82. Fresenius Kabi Sales Value Proportion by Application in 2024

Table 83. Fresenius Kabi Sales Value Proportion by Geographic Area in 2024

Table 84. Fresenius Kabi Denosumab Injection SWOT Analysis

Table 85. Fresenius Kabi Recent Developments

Table 86. Dr. Reddy's Laboratories Corporation Information

Table 87. Dr. Reddy's Laboratories Description and Major Businesses

Table 88. Dr. Reddy's Laboratories Product Models, Descriptions and Specifications

Table 89. Dr. Reddy's Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Dr. Reddy's Laboratories Sales Value Proportion by Product in 2024

Table 91. Dr. Reddy's Laboratories Sales Value Proportion by Application in 2024

Table 92. Dr. Reddy's Laboratories Sales Value Proportion by Geographic Area in 2024

Table 93. Dr. Reddy's Laboratories Denosumab Injection SWOT Analysis

Table 94. Dr. Reddy's Laboratories Recent Developments

Table 95. Alvotech Corporation Information

Table 96. Alvotech Description and Major Businesses

Table 97. Alvotech Product Models, Descriptions and Specifications

Table 98. Alvotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Alvotech Recent Developments

Table 100. Lotus Pharmaceutical Corporation Information

Table 101. Lotus Pharmaceutical Description and Major Businesses

Table 102. Lotus Pharmaceutical Product Models, Descriptions and Specifications

Table 103. Lotus Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Lotus Pharmaceutical Recent Developments

Table 105. Intas Pharmaceuticals Corporation Information

Table 106. Intas Pharmaceuticals Description and Major Businesses

Table 107. Intas Pharmaceuticals Product Models, Descriptions and Specifications

Table 108. Intas Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Intas Pharmaceuticals Recent Developments

Table 110. Qilu Pharmaceutical Corporation Information

Table 111. Qilu Pharmaceutical Description and Major Businesses

Table 112. Qilu Pharmaceutical Product Models, Descriptions and Specifications

Table 113. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Qilu Pharmaceutical Recent Developments

Table 115. Jiangsu T-mab BioPharma Corporation Information

Table 116. Jiangsu T-mab BioPharma Description and Major Businesses

Table 117. Jiangsu T-mab BioPharma Product Models, Descriptions and Specifications

Table 118. Jiangsu T-mab BioPharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Jiangsu T-mab BioPharma Recent Developments

Table 120. Boan Biotech Corporation Information

Table 121. Boan Biotech Description and Major Businesses

Table 122. Boan Biotech Product Models, Descriptions and Specifications

Table 123. Boan Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. Boan Biotech Recent Developments

Table 125. Key Raw Materials Distribution

Table 126. Raw Materials Key Suppliers

Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 128. Milestones in Production Technology Evolution

Table 129. Distributors List

Table 130. Market Trends and Market Evolution

Table 131. Market Drivers and Opportunities

Table 132. Market Challenges, Risks, and Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

List of Figures

Figure 1. Denosumab Injection Product Picture

Figure 2. Global Denosumab Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. 60mg per Vial Product Picture

Figure 4. 120mg per Vial Product Picture

Figure 5. Global Denosumab Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Giant Cell Tumor of Bone

Figure 7. Multiple Myeloma

Figure 8. Hypercalcemia of Malignant Tumors

Figure 9. Osteolytic Bone Metastasis of Solid Tumors

Figure 10. Denosumab Injection Report Years Considered

Figure 11. Global Denosumab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 13. Global Denosumab Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 14. Global Denosumab Injection Revenue Market Share by Region (2020-2031)

Figure 15. Global Denosumab Injection Sales (2020-2031) & (K Units)

Figure 16. Global Denosumab Injection Sales (CAGR) by Region (2020-2031) (K Units)

Figure 17. Global Denosumab Injection Sales Market Share by Region (2020-2031)

Figure 18. Top 5 and Top 10 Manufacturers Denosumab Injection Sales Volume Market Share in 2024

Figure 19. Global Denosumab Injection Revenue Market Share Ranking (2024)

Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 21. 60mg per Vial Revenue Market Share by Manufacturer in 2024

Figure 22. 120mg per Vial Revenue Market Share by Manufacturer in 2024

Figure 23. Global Denosumab Injection Sales Market Share by Type (2020-2031)

Figure 24. Global Denosumab Injection Revenue Market Share by Type (2020-2031)

Figure 25. Global Denosumab Injection Sales Market Share by Application (2020-2031)

Figure 26. Global Denosumab Injection Revenue Market Share by Application (2020-2031)

Figure 27. North America Denosumab Injection Sales YoY (2020-2031) & (K Units)

Figure 28. North America Denosumab Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 29. North America Top 5 Manufacturers Denosumab Injection Sales Revenue (US$ Million) in 2024

Figure 30. North America Denosumab Injection Sales Volume (K Units) by Type (2020- 2031)

Figure 31. North America Denosumab Injection Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 32. North America Denosumab Injection Sales Volume (K Units) by Application (2020-2031)

Figure 33. North America Denosumab Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 34. US Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 35. Canada Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 36. Mexico Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 37. Europe Denosumab Injection Sales YoY (2020-2031) & (K Units)

Figure 38. Europe Denosumab Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 39. Europe Top 5 Manufacturers Denosumab Injection Sales Revenue (US$ Million) in 2024

Figure 40. Europe Denosumab Injection Sales Volume (K Units) by Type (2020-2031)

Figure 41. Europe Denosumab Injection Sales Revenue (US$ Million) by Type (2020-2031)

Figure 42. Europe Denosumab Injection Sales Volume (K Units) by Application (2020-2031)

Figure 43. Europe Denosumab Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 44. Germany Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 45. France Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 46. U.K. Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 47. Italy Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 48. Russia Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 49. Asia-Pacific Denosumab Injection Sales YoY (2020-2031) & (K Units)

Figure 50. Asia-Pacific Denosumab Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Asia-Pacific Top 8 Manufacturers Denosumab Injection Sales Revenue (US$ Million) in 2024

Figure 52. Asia-Pacific Denosumab Injection Sales Volume (K Units) by Type (2020- 2031)

Figure 53. Asia-Pacific Denosumab Injection Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 54. Asia-Pacific Denosumab Injection Sales Volume (K Units) by Application (2020-2031)

Figure 55. Asia-Pacific Denosumab Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 56. Indonesia Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 57. Japan Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 58. South Korea Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 59. China Taiwan Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 60. India Denosumab Injection Revenue (2020-2031) & (US$ Million)

Figure 61. Central and South America Denosumab Injection Sales YoY (2020-2031) & (K Units)

Figure 62. Central and South America Denosumab Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 63. Central and South America Top 5 Manufacturers Denosumab Injection Sales Revenue (US$ Million) in 2024

Figure 64. Central and South America Denosumab Injection Sales Volume (K Units) by Type (2021-2031)

Figure 65. Central and South America Denosumab Injection Sales Revenue (US$ Million) by Type (2020-2031)

Figure 66. Central and South America Denosumab Injection Sales Volume (K Units) by Application (2020-2031)

Figure 67. Central and South America Denosumab Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 68. Brazil Denosumab Injection Revenue (2020-2025) & (US$ Million)

Figure 69. Argentina Denosumab Injection Revenue (2020-2025) & (US$ Million)

Figure 70. Middle East, and Africa Denosumab Injection Sales YoY (2020-2031) & (K Units)

Figure 71. Middle East and Africa Denosumab Injection Revenue YoY (2020-2031) & (US$ Million)

Figure 72. Middle East and Africa Top 5 Manufacturers Denosumab Injection Sales Revenue (US$ Million) in 2024

Figure 73. Middle East and Africa Denosumab Injection Sales Volume (K Units) by Type (2021-2031)

Figure 74. South America Denosumab Injection Sales Revenue (US$ Million) by Type (2020-2031)

Figure 75. Middle East and Africa Denosumab Injection Sales Volume (K Units) by Application (2020-2031)

Figure 76. Middle East and Africa Denosumab Injection Sales Revenue (US$ Million) by Application (2020-2031)

Figure 77. GCC Countries Denosumab Injection Revenue (2020-2025) & (US$ Million)

Figure 78. Turkey Denosumab Injection Revenue (2020-2025) & (US$ Million)

Figure 79. Egypt Denosumab Injection Revenue (2020-2025) & (US$ Million)

Figure 80. South Africa Denosumab Injection Revenue (2020-2025) & (US$ Million)

Figure 81. Denosumab Injection Industry Chain Mapping

Figure 82. Regional Denosumab Injection Manufacturing Base Distribution (%)

Figure 83. Global Denosumab Injection Production Market Share by Region (2020-2031)

Figure 84. Denosumab Injection Production Process

Figure 85. Regional Denosumab Injection Production Cost Structure

Figure 86. Channels of Distribution (Direct Vs Distribution)

Figure 87. Bottom-up and Top-down Approaches for This Report

Figure 88. Data Triangulation

Figure 89. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions